Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 2Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Renal Cell 10Breast Neoplasms 5Sarcoma 2Prostatic Neoplasms 2Melanoma 2Gastrointestinal Stromal Tumors 2Urinary Bladder Neoplasms 1Solitary Fibrous Tumors 1Solid Tumors Refractory to Standard Therapy 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Osteosarcoma 1Neoplasms 1Neoplasm Metastasis 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Kidney Neoplasms 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1Hemangioendothelioma 1Fatigue 1Colorectal Neoplasms 1Chondrosarcoma, Extraskeletal Myxoid 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 74Nivolumab 53Ipilimumab 42Cyclophosphamide 32Interleukin-2 24aldesleukin 23Temozolomide 17fludarabine 16Biopsy 11trametinib 10fludarabine phosphate 10dabrafenib 10spartalizumab 8Paclitaxel 8Dacarbazine 8sargramostim 7cemiplimab 7binimetinib 7Cisplatin 7Bevacizumab 7poly ICLC 6lenvatinib 6epacadostat 6Radiotherapy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5encorafenib 5atezolizumab 5Vemurafenib 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Melanoma × Sunitinib × Clear all
NCT00496223 2011-02-23

A Phase I/II Study of Sunitinib and Dacarbazine

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Terminated
11 enrolled
Dermatologic

Melanoma

NCT00304200 2009-02-05

Temodar and Sutent as Therapy for Melanoma

Northern California Melanoma Center

Phase 1/2 Terminated
7 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡